Correlation of Findings in Advanced MRI Techniques with Global Severity Scales in Patients with Parkinson Disease

Academic Radiology

Volumn 18, Issue 2, 2011, Pages 235-241

  Modrego, Pedro J ^a   Fayed, Nicolás ^b   Artal, Jorge ^a   Olmos, Salvador ^c  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b HOSPITAL QUIRÓN   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Diffusion tensor imaging; Magnetic resonance spectroscopy; Parkinson disease

Indexed keywords

GLUTAMIC ACID; GLUTAMINE;

AGED; ANTERIOR CINGULATE; ARTICLE; BASAL GANGLION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION TENSOR IMAGING; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; FEMALE; FRACTIONAL ANISOTROPY; HUMAN; MALE; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SUBSTANTIA NIGRA; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; BRAIN; CHOLINE; CORPUS STRIATUM; CREATINE; DIFFUSION TENSOR IMAGING; DIPEPTIDES; FEMALE; GLUTAMIC ACID; GLUTAMINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; SUBSTANTIA NIGRA;

EID: 78651061756     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acra.2010.09.022     Document Type: Article

References (39)

1. Fayed N., Olmos S., Morales H., et al. Physical basis of magnetic resonance spectroscopy and its application to central nervous system diseases. Am J Appl Sci 2006, 3:1836-1845.
2. Holshouser B.A., Komu M., Moller H.E., et al. Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a multicenter pilot study. Magn Reson Med 1995, 33:589-594.
3. Camicioli R.M., Hanstock C.C., Bouchard T.P., et al. Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson's disease. Mov Disord 2007, 22:382-386.
4. Firbank M.J., Harrison R.M., O'Brian J.T. A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. Dement Geriatr Cogn Disord 2002, 14:64-76.
5. Taylor-Robinson S.D., Turjanski N., Bhattacharya S., et al. A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease. Metab Brain Dis 1999, 14:45-55.
6. Davie C.A., Wenning G.K., Barker G.J., et al. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol 1995, 37:204-210.
7. Tedeschi G., Litvan I., Bonavita S., et al. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain 1997, 120:1541-1552.
8. O'Neil J., Schuff N., Marks W.J., et al. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Movement Disord 2002, 17:917-927.
9. Summerfield C., Gómez-Ansón B., Tolosa E., et al. Dementia in Parkinson disease: a proton magnetic resonance spectroscopy study. Neurol Arch 2002, 59:1415-1420.
10. Jones D.K., Williams S.C., Gasston D., et al. Isotropic resolution diffusion tensor imaging with whole brain acquisition in a clinically acceptable time. Hum Brain Mapp 2002, 15:216-230.
11. Karagulle Kendi A.T., Lehericy S., Luciana M., et al. Altered diffusion in the frontal lobe in Parkinson disease. AJNR Am J Neuroradiol 2008, 29:501-505.
12. Chan L.L., Rumpel H., Yap K., et al. Case control study of diffusion tensor imaging in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007, 78:1383-1386.
13. Boska M.D., Hasan K.M., Kibuule D., et al. Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease. Neurobiol Dis 2007, 26:590-596.
14. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114:2283-2301.
15. Martin W.R., Wieler M., Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008, 70:1411-1417.
16. Gelb D.J., Oliver E., Gilman S. Diagnostic criteria for Parkinson's disease. Arch Neurol 1999, 56:33-39.
17. Provencher S.W. Estimation of metabolite concentrations from localised in vivo proton NMR spectra. Magn Reson Med 1993, 30:672-679.
18. Fayed N., Modrego P.J., Medrano J. Comparative test-retest reliability of metabolite values assessed with magnetic resonance spectroscopy of the brain. The LCModel versus the manufacturer software. Neurol Res 2009, 31:472-477.
19. Basser P.J., Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B 1996, 111:209-219.
20. Oikawa H., Sasaki M., Tamakawa Y., et al. The substantia nigra in Parkinson disease: proton density weighted spin-echo and fast short inversion time inversion recovery MR findings. AJNR Am J Neuroradiol 2002, 23:1747-1756.
21. Vaillancourt D.E., Spraker M.B., Prodoehl J., et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009, 72:1378-1384.
22. Abe O., Aoki S., Hayashi N., et al. Normal aging in the central nervous system: quantitative MR diffusion-tensor analysis. Neurobiol Aging 2002, 23:433-441.
23. Tievsky A.L., Ptak T., Farkas J. Investigation of apparent diffusion coefficient and diffusion tensor anisotropy in acute and chronic multiple sclerosis lesions. Am J Neuroradiol 1999, 20:1491-1499.
24. Yoshikawa K., Nakata Y., Yamada K., et al. Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. J Neurol Neurosurg Psychiatry 2004, 75:481-484.
25. Griffith H.R., Okonkwo O.C., O'Brien T., et al. Reduced brain glutamate in patients with Parkinson's disease. NMR Biomed 2008, 21:381-387.
26. Oz G., Terpstra M., Tkác I., et al. Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations. Magn Reson Med 2006, 55:296-301.
27. Kickler N., Krack P., Fraix V., et al. Glutamate measurement in Parkinson's disease using MRS at 3 T field strength. NMR Biomed 2007, 20:757-762.
28. Taylor-Robinson S.D., Turjanski N., Bhattacharya S., et al. A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease. Metab Brain Dis 1999, 14:45-55.
29. Clarke C.E., Lowry M., Horsman A. Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy. Mov Disord 1997, 12:297-301.
30. Clarke C.E., Lowry M. Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. Eur J Neurol 2000, 7:661-665.
31. Gruetter R., Weisdorf S.A., Rajanayagan V., et al. Resolution improvements in in vivo 1H NMR spectra with increased magnetic field strength. J Magn Reson 1998, 135:260-264.
32. Di Costanzo A., Trojsi F., Tosetti M., et al. High-field proton MRS of human brain. Eur J Radiol 2003, 48:146-153.
33. Kickler N., Krack P., Fraix V., et al. Glutamate measurement in Parkinson's disease using MRS at 3 T field strength. NMR Biomed 2007, 20:757-762.
34. Schubert F., Gallinat J., Seifert F., et al. Glutamate concentrations in human brain using single voxel proton magnetic resonance spectroscopy at 3 Tesla. Neuroimage 2004, 21:1762-1771.
35. Coyle J.T., Bird S.J., Evans R.H., et al. Excitatory amino acid neurotoxins: selectively and mechanisms of action. Neurosci Res Prog 1981, 19:331-427.
36. Bosman D.K., Deutz N.E., De Graaf A.A., et al. Changes in brain metabolism during hyperammonemia and acute liver failure: Results of a comparative 1H NMR spectroscopy and biochemical investigation. Hepatology 1990, 12:281-290.
37. Häussinger D., Kircheis G., Fischer R., et al. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?. J Hepatol 2000, 32:1035-1038.
38. Duchesne S., Rolland Y., Vérin M. Automated computer differential classification in parkinsonian syndromes via pattern analysis on MRI. Acad Radiol 2009, 16:61-70.
39. Raff U., Hutchinson M., Rojas G.M., et al. Inversion recovery MRI in idiopathic Parkinson disease is a very sensitive tool to assess neurodegeneration in the substantia nigra: preliminary investigation. Acad Radiol 2006, 13:721-727.